AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01477242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 2mg (5mL) in \< 15 kg and 4mg (10mL) in 15kg to 30kg
Study NCT01477242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 2mg (5mL) in \< 15 kg and 4mg (10mL) in 15kg to 30kg
Study NCT02271503 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
Study NCT02271503 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX203 180 mg
Description: IPX203 containing 45 mg carbidopa and180 mg levodopa
Study NCT02271503 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX203 270 mg
Description: IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
Study NCT02271503 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rytary 195 mg
Description: Rytary 48.75Mg-195Mg Extended-Release Capsule
Study NCT02271503 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rytary 145 mg
Description: Rytary 36.25Mg-145Mg Extended-Release Capsule
Study NCT02207933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AP shifting training
Description: AP shifting training in addition to gait training 3 times a week for 6 weeks
Study NCT02207933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gait training
Description: Gait training only for 3 times a week for 6 weeks.
Study NCT03195907 — intervention group
Intervention type: OTHER
Intervention: Pulmonary physiotherapy
Study NCT00487539 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
Study NCT00487539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -> 50 mg arm group and at Week 2 for Golimumab 200 mg -> 100 mg arm group.
Study NCT00487539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 200 mg
Description: Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -> 100 mg arm group and at Week 2 for Golimumab 400 mg -> 200 mg arm group.
Study NCT00487539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 400 mg
Description: Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -> 200 mg arm group.
Study NCT00487539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -> 50 mg arm group.
Study NCT03655964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: At Day 4 of stroke onset, patients with clinic BP >160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset
Study NCT03655964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: At Day 4 of stroke onset, patients with clinic BP >160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset
Study NCT03655964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No antihypertensive treatment
Description: Patients will be left without treatment
Study NCT02813200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide® Diskus® 500/550 μg
Description: Every day during 7 days
Study NCT02813200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultibro® Breezhaler® 110/50 μg
Description: Every day during 7 days
Study NCT02813200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva® Respimat® 2,5 μg
Description: Every day during 7 days
Study NCT03592446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical vagus nerve stimulation
Description: All subjects receive electrical VNS stimulation at cymba conchae.
Study NCT03592446 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: All subjects receive electrical stimulation at earlobe.
Study NCT00229307 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure (PE) therapy
Description: 20 minutes exposure
Study NCT00229307 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure (PE) therapy
Description: 40 minutes exposure
Study NCT04113772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: Measure bio equivalency/efficacy of nitinosine and orfadin
Study NCT04113772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orfadin
Description: Orfadin
Study NCT02877342 — intervention group
Intervention type: OTHER
Intervention: Pre-hospital notification
Description: Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
Study NCT00964977 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Patients receive radiation within 6 weeks after surgery. At primary tumour site and involved lymph node level a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled according to the rules of ICRU report 50.
Study NCT02175680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: CCR5 Antagonist
Study NCT02175680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Historical data
Description: Historical data (i.e., time to HIV-1 RNA viral load > 500 copies/mL of 29 days).
Study NCT03357627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablets.
Study NCT03357627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets.
Study NCT03612986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SYALOX® 300 Plus
Description: Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
Study NCT03612986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator. No chemical effect expected
Study NCT02692066 — intervention group
Intervention type: BIOLOGICAL
Intervention: varicella vaccine
Study NCT01060059 — intervention group
Intervention type: DRUG
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Study NCT01060059 — intervention group
Intervention type: DRUG
Intervention: basal insulin
Description: subcutaneous injection, dosing according to physician's clinical judgment
Study NCT04397094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theracal LC
Description: pulpotomy
Study NCT04397094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Pulpotomy
Study NCT00501813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatectomy
Description: irregular Hepatectomy
Study NCT00501813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE combined with local regional therapies without hepatectomy
Description: TACE combined with RFA, MCT, PEI, and so on.
Study NCT03575858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barrel shaped interdental brush
Description: Barrel shaped interdental brush Size SS 0.8mm
Study NCT03575858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered interdental brush
Description: Tapered interdental brush Size SS 0.6mm
Study NCT01459458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Planning-based Partner Violence Intervention
Description: The intervention includes three major components:~1. Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.~2. Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.~3. Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed.
Study NCT01035905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode
Study NCT01035905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode
Study NCT02448732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACM-1
Description: intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
Study NCT00091832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab administered by subcutaneous injection
Study NCT00091832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Bisphosphonates
Description: Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
Study NCT04369066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples (collection of 5 mL of blood in a dry tube)
Description: A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.~The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0, between 6 weeks and 3 months ,6 months and 12 months post-inclusion.~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples shall be performed, if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The serum samples will be extracted and collected prospectively from the blood samples.~For each blood sample, a sample number will be assigned by the laboratory management system of the Department of Biology at Institut Curie.
Study NCT04369066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasopharyngeal swabs
Description: The nasopharyngeal swabs will be performed between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff with at least one of the following criteria: have had RT-PCR+, and/or presence of antibodies at the 95% threshold, and/or anosmia/ageusia, and/or digestive syndrome with associated respiratory signs.~The nasopharyngeal swab shall also be proposed to volunteers not meeting the above listed criteria to have a control group (about 100 volunteers).~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) infection between 2 sampling times, nasopharyngeal swabs shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The nasopharyngeal swabs will be performed at T0 for Institute Pasteur staff so 4 times in total.
Study NCT02972164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss program for school children
Description: The intervention involves developing social and emotional competences, promotion of healthy lifestyle, use of activity monitoring devices to promote increased activity and enlisting family to maintain weight loss in the long term.~The intervention group receives all program components: 1. Parent information sessions and orientation, 2. Two week intensive weight loss and lifestyle education camp, 3. after school clubs for consolidation (including physical activity and lifestyle education), and 4. wearable sensors and social media modules with parental involvement. Assessed outcomes include pre- and post-measurement at each phase included: weight, height, BMI, waist circumference, blood pressure, physical activity, dietary intakes, self-esteem, and subjective well-being.
Study NCT00740350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Logan Basic
Description: Logan Basic chiropractic adjustments during pregnancy.
Study NCT04490837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA and Rapid test to detect antibodies against COVID-19
Description: Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
Study NCT02067039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick in home & Sure Check HIV tests
Description: Provision of OraQuick in home \& Sure Check HIV tests
Study NCT04385654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (240 mg,ivgtt,q3w) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
Study NCT04385654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib (5 mg,po,qd) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
Study NCT01972074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Capsule
Study NCT01972074 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT03597048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Curriculum
Description: The curriculum intervention is a three- module, three-hour curriculum delivered by teachers in sixth grade classrooms over a three- to six-day period. The curriculum is designed to increase knowledge and improve attitudes about mental illnesses so as to improve the school climate with respect to mental illness stigma and encourage help seeking for youth in need.
Study NCT03597048 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Curriculum
Description: The curriculum intervention is a three- module, three-hour curriculum delivered by teachers in sixth grade classrooms over a three- to six-day period. The curriculum is designed to increase knowledge and improve attitudes about mental illnesses so as to improve the school climate with respect to mental illness stigma and encourage help seeking for youth in need.
Study NCT03597048 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact
Description: The contact intervention involves two college students-a 27-year-old male with a history of bipolar I disorder and a 24-year-old female with a history of bipolar II disorder-who each make a ten-minute in-class presentation (20 minutes total) describing onset and course of their symptoms, hospitalizations and treatments, their feelings about the illness, coping strategies, and impact of the illness on social relationships and functioning at school and work.
Study NCT03597048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contact
Description: The contact intervention involves two college students-a 27-year-old male with a history of bipolar I disorder and a 24-year-old female with a history of bipolar II disorder-who each make a ten-minute in-class presentation (20 minutes total) describing onset and course of their symptoms, hospitalizations and treatments, their feelings about the illness, coping strategies, and impact of the illness on social relationships and functioning at school and work.
Study NCT03597048 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Materials
Description: The materials intervention is implemented by teachers who prominently display posters in the classroom for two weeks and provide students with bookmarks. The materials focus on individuals' with mental illnesses emphasizing their personal traits and abilities as opposed to language that labels a person as mentally ill.
Study NCT03597048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Materials
Description: The materials intervention is implemented by teachers who prominently display posters in the classroom for two weeks and provide students with bookmarks. The materials focus on individuals' with mental illnesses emphasizing their personal traits and abilities as opposed to language that labels a person as mentally ill.
Study NCT02508194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510
Description: RSV soluble fusion protein (sF) antigen plus glucopyranosyl lipid A in stable emulsion (GLA-SE) adjuvant
Study NCT02508194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV
Description: Marketed Inactivated Influenza Vaccine
Study NCT02508194 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IIV
Description: Marketed Inactivated Influenza Vaccine
Study NCT02508194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sterile Saline
Study NCT02235194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid and chromium-picolinate containing drink
Description: Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
Study NCT02235194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amino Acid and chromium-picolinate containing drink
Description: Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
Study NCT02235194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Drink
Description: Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
Study NCT02235194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drink
Description: Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
Study NCT00393874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Sleep Intervention
Description: Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
Study NCT00393874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
Study NCT00393874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
Study NCT02113631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Study NCT02113631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Study NCT02113631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN
Description: Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks
Study NCT02113631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks
Study NCT03434379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
Study NCT03434379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle
Study NCT03434379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle